Clinical and Genetic Analysis of Pediatric Neurodevelopmental Disorders With Complex Chromosomal Rearrangements in Two Cases Authors: Jiaci Li, Wenxuan Fan, Nan Liu, Shuyue Zhang, Ping Wang, Chunyu Gu, Jianbo Shu Published: 2026 ABSTRACT ABSTRACTObjectiveOur study investigates the impact of junction breakpoints of complex chromosomal rearrangements (CCRs) on developmental delay and intermittent epilepsy in children, aiming to elucidate the underlying genetic mechanisms.MethodsWe reported a patient with developmental delay in family 1, and we reported a patient with intermittent epileptic seizures in family 2. Karyotype analysis was used to detect chromosomal abnormalities. Whole exome sequencing (WES) and/or whole genome sequencing (WGS) can further assist in identifying the genetic etiology.ResultsOur findings revealed a central inversion rearrangement on chromosome 3 affecting the Roundabout Guidance Receptor 1 (ROBO1), DnaJ Heat Shock Protein Family Member C13 (DNAJC13), and Acyl‐CoA Dehydrogenase Family Member 11 (ACAD11) genes in patient 1, suggesting its potential pathogenic role in developmental delays. In another patient, we identified a complex rearrangement involving chromosome 1, coupled with a heterozygous mutation in KCNA2 NM_004974.4:c.347A>C (p.Tyr116Ser), indicating a strong association with intermittent seizures.ConclusionsCombining chromosome karyotype analysis with WES and/or WGS can accurately locate chromosomal breakpoints and provide more accurate genetic information. It is an important approach for integrated diagnosis.Keywords: chromosomal breakpoints, karyotype analysis, WES, WGS Introduction The focus of this study is on developmental delay and intermittent epilepsy in children, significantly affecting patients' daily lives and development and imposing a huge economic burden on families and society (Albaradie et al. 2021; Hiraide et al. 2021; Symonds et al. 2021). Developmental delay may lead to learning difficulties and social impairments, while epilepsy may affect patients' safety and quality of life (Albaradie et al. 2021; Aldosari and Aldosari 2024). Currently, the main diagnostic and therapeutic methods for these diseases rely on clinical assessment and drug treatment; however, these methods have obvious limitations, including the lack of personalized treatment strategies and the inability to identify genetic factors that may cause these diseases (Inui et al. 2015; Li et al. 2025; Dinoi et al. 2022). Therefore, this study is of great importance for our understanding of the genetic basis of neurodevelopmental disorders (NDDs). The methodologies employed in the study include chromosome karyotype analysis and WES and/or WGS. Karyotype analysis is considered the “gold standard” for detecting chromosomal diseases, as it can identify chromosomal abnormalities larger than 5–10 Mb, including numerical chromosomal abnormalities, large structural abnormalities, and balanced translocation carriers (Wan and Ma 2024; Wan et al. 2017). However, this technique is unable to detect monogenic diseases and microdeletion or microduplication syndromes caused by smaller fragment changes (Wan and Ma 2024; Wan et al. 2017). WES targets the exon regions of the genome and can efficiently detect variations associated with genetic diseases, given that 85% of pathogenic mutations occur in these regions, thus providing high sensitivity and accuracy in identifying pathogenic genes (LaDuca et al. 2017). WGS encompasses the entire genome, including exons, introns, and other non‐coding regions (Brlek et al. 2024). It allows for a more comprehensive understanding of genetic information when addressing complex and unclear genetic diseases, ultimately increasing the diagnostic rate (Brlek et al. 2024). Karyotype analysis enables the detection of chromosomal abnormalities, while WES and/or WGS can help identify both common and rare genetic variants linked to the observed phenotypes. By integrating these methods, we expect to gain a more comprehensive understanding of the genetic basis of NDDs. The comprehensive approach has the potential to enhance diagnostic accuracy and open up new avenues for personalized treatment strategies. In conclusion, this study aims to provide valuable insights into the genetic factors associated with developmental delay and seizures. Combining chromosome karyotype analysis with WES and/or WGS can provide more accurate genetic information, which is an important approach for integrated diagnosis. Materials and Methods Ethical Compliance Pre‐ and post‐test genetic counselling was provided to the patients and their parents by a certified genetic counsellor. Written informed consent was obtained from the patients' parents for participation in the study, which specifically included consent for genetic testing, the use of anonymized data for research purposes, and the publication of clinical details and any associated medical images. The study was approved by the Independent Ethics Committee (IEC) of Tianjin Children's Hospital (Approval Reference Number: 2024‐SBKT‐041) on October 29, 2024. The study was conducted in compliance with the ethical principles in the Declaration of Helsinki and International Ethical Guidelines for Human Biomedical Research. Study Subjects In family 1, an 8‐month‐old female patient was admitted to Tianjin Children's Hospital due to experiencing “psychomotor retardation for 2 months”. She had poor rolling and brief sitting with support. She was unable to sit independently. The developmental quotient assessment confirmed a diagnosis of psychomotor developmental delay. The dynamic electroencephalogram was normal, while the head MRI revealed widening of the extracerebral space and nodular areas with slightly long T2 signal shadows in the left sigmoid sinus region. Additionally, thyroid function tests indicated that the TT4 level was 160.83 mmol/L. LC–MS/MS assays of blood and GC–MS/MS assays of urine were within the normal range in the patient. The patient exhibited decreased muscle tone in all four limbs and exotropia in her right eye (Table 1). TABLE 1Characteristics of patients.PatientsPatient 1Patient 2Age8 months4 yearsSexFemaleMaleMajor clinical featuresPsychomotor developmental delay noted for 2 months; poor rolling, brief sitting with support, unable to sit independently; decreased muscle tone in all four limbs; right exotropiaIntermittent seizures for > 4 years (onset at 6 months), 8–9 episodes; generalized clonic or focal to bilateral tonic‐clonic, duration 1–10 min; febrile sensitivity; mild language delay, otherwise normal developmentNeuroimagingBrain MRI: widened extracerebral spaces; optic nerve MRI: normalBrain MRI: no significant abnormalitiesEEG findingsNormalAwake generalized spike‐and‐wave and polyspike‐and‐wave dischargesInheritanceMaternalDe novoKaryotype46, XX, inv (3) (p13q23)46, XY, inv (1) (pter → p13: q21 → p13: q21 → qter)Sequencing findingsWGS: inversion breakpoint likely disrupting ROBO1/DNAJC13/ACAD11 WES: heterozygous variant in KCNA2 NM_004974.4:c.347A>C (p.Tyr116Ser)Variant classificationLikely pathogenic structural variant (pericentric inversion)Novel missense variant (PS2+PM2_Supporting+PP2+PP3_Moderate, likely pathogenic)Final Diagnostic InterpretationGlobal developmental delay may be due to chromosomal inversion involving ROBO1/DNAJC13/ACAD11 Epilepsy due to KCNA2 variant Characteristics of patients. A 4‐year‐old male patient from family 2 was admitted with a history of intermittent convulsions lasting over four years. He had his first seizure at six months of age, presenting as generalized clonic or focal seizures. His focal seizures later progressed to generalized clonic seizures. In total, he experienced 8–9 seizures, with two classified as afebrile and the remainder as febrile convulsions. The dynamic electroencephalogram revealed abnormalities, including generalized spike‐and‐slow‐wave and polyspike‐and‐slow‐wave paroxysms during wakefulness. The chest CT scan indicated thickening of bilateral lung images, while the head MRI showed no abnormalities. However, there was thickening of the mucosa in both the bilateral maxillary and ethmoid sinuses (Table 1). Karyotype Analysis Peripheral blood samples were collected from the patient and their parents from two families using heparin sodium anticoagulant tubes. A volume of 1 mL was utilized for cell culture, which was subsequently harvested and prepared for G‐banding staining. After approximately three days of culture, karyotype analysis was conducted. The karyotypes were described in accordance with the International System of Nomenclature for Human Cytogenomics (ISCN 2016). WGS and WES Analysis Genomic DNA was extracted from the patient and their parents in two families. The extracted DNA was then fragmented, and library preparation was carried out using a specialized kit. WGS was performed for Patient 1, and WES was performed for Patient 2 in our study. WES was performed on the Illumina platform, and WGS was performed on the DNBSEQ‐T7 platform. The genome build used was hg19. Mean depth for WES was 120×, and for WGS was 50×. Coverage thresholds were more than 20 × in 98% of the target sequence. Variant calling for WES was performed using GATK, and for WGS was performed using Sentieon. The WES filtering strategy was as follows: ANNOVAR was used to perform functional annotation of the detected mutation sites. These sites were then cross‐referenced with multiple databases, including the 1000 Genomes Project, ESP6500, ExAC, gnomAD, and dbSNP. Additionally, variant deleteriousness prediction was conducted using software tools such as REVEL, SIFT, PolyPhen‐2, MutationTaster, and GERP++. The WGS filtering strategy was as follows: The filtering criteria of Sentieon were not a single threshold, but a set of multiple filtering mechanisms automatically applied during the variant detection process. These mechanisms performed initial screening of variants based on various parameters. The workflow for detecting structural variants in WGS was as follows: First, sequencing adapters were trimmed using cutadapt. Then, the filtered sequencing reads were aligned to the hg19 reference genome using Sentieon BWA. Subsequently, duplicate reads introduced by PCR amplification were identified and marked. These duplicate sequences cannot serve as independent evidence of variants and must be either marked or removed. The DNAscope module was then used to identify potential variants, followed by application of the DNAModelApply machine learning model to further select true and reliable variants. The CNV analysis method was as follows: The coverage tool of the CNVkit software (https://cnvkit.readthedocs.io/en/stable/) was used to calculate the coverage depth of target and off‐target regions from the aligned BAM file, generating target.cnn and antitarget.cnn files. For CNV analysis, appropriate control samples need to be selected for data normalization. We selected a suitable set of control data to ensure that the fluctuation of the test sample data was minimized. The fix, segment, and call tools of the CNVkit software were then used to calculate the relative copy number of the test sample. WES/WGS candidate variants were independently validated by Sanger sequencing in the proband and available family members. Results Family 1 Karyotype analysis showed that Patient 1 had structural abnormalities of chromosome 3, which was reported as 46, XX, der (3) (Figure 1). The patient's father's karyotype was 46, XY, which was normal. However, the patient's mother's karyotype result showed an inversion of chromosome 3, and her mother's karyotype was 46, XX, inv (3) (p13q23) (Figure 2). WGS results showed no clear pathogenic chromosomal structural variants, copy number variants, point mutations, or mitochondrial variants associated with disease phenotypes. Therefore, we hypothesize that chromosomal variants are inherited from her mother. We corrected the patient's karyotype as 46, XX, inv (3) (p13q23). Chromosomal karyotype of patient 1. Chromosomal karyotype of patient 1's mother. Combined with the karyotype results and reanalysis of the WGS data, a pericentric inversion rearrangement of chromosome 3 was found with the breakpoint approximately at chr3:79128163–132,266,046 (sequence length 53,137,883 bp) (Figures 3 and 4). Breakpoint 1 was located in the ROBO1 gene. Breakpoint 2 was located between DNAJC13 and ACAD11, but it was closer to DNAJC13. Inversion rearrangement may lead to abnormal expression of these genes. Gene break site of patient 1 (A: Schematic diagram showing the position of breakpoint 1; B: Schematic diagram showing the position of breakpoint 2). Schematic diagram of chromosomal rearrangements and gene breakpoints in patient 1. Family 2 Karyotype analysis showed that Patient 2 had structural abnormalities of chromosome 1, which was reported as 46, XY, der (1) (pter → p13:?: q21 → p13: q21 → qter) (Figure 5). His parents' karyotypes were normal. CNV analysis revealed no abnormalities in gene copy number variation in the patient and his parents. Therefore, the karyotype of the patient was inferred to be 46, XY, inv (1) (pter → p13: q21 → p13: q21 → qter). In addition, screening of genetic variants in the patient by WES analysis revealed a heterozygous variant: KCNA2 NM_004974.4:c.347A>C (p.Tyr116Ser), which was a novel variant (Figure 6). The ACMG criteria for the KCNA2 variant were “Likely Pathogenic”. The specific evidence codes used (PS2 + PM2_Supporting + PP2 + PP3_Moderate) were as follows: PS2 (de novo in a patient with the disease and no family history), PM2_ Supporting (absent from controls in Exome Sequencing Project, 1000 Genomes or ExAC databases), PP2 (missense variant in a gene has a low rate of benign missense variation and missense variants are a common mechanism of disease), and PP3_Moderate (multiple lines of computational evidence support a deleterious effect on the gene or gene product). In addition, the variant was predicted to be deleterious by PolyPhen‐2 (score 1.000, probably damaging) (Figure 7). Conservation analysis showed that the affected amino acid residue was highly conserved across species using DNAMAN (Figure 8). The KCNA2 mutations can cause epileptic encephalopathy type 32 in early infants with autosomal dominant inheritance, which is compatible with the patient's clinical phenotype. Chromosomal karyotype of patient 2. WES results of patient 2 and his parents. Conservation analysis of KCNA2 protein sequences across different species (amino acid positions of variants are highlighted in a red box). Prediction of KCNA2 variant conservation among different species. Discussion and Conclusions NDDs are a group of highly heterogeneous conditions that impair social, cognitive, and emotional functioning in children, with genetic factors playing a critical role in their etiology (Blesson and Cohen 2020; Gao et al. 2021). Globally, the prevalence of NDDs is estimated at approximately 2%–4% (Sabariego‐Navarro et al. 2022), and genetic causes account for about 35% of children with epilepsy accompanied by developmental delay (Sabariego‐Navarro et al. 2022). The integration of conventional cytogenetics with high‐throughput sequencing technologies has been widely applied in clinical diagnostics (Dardas et al. 2025). In this study, we investigated two pediatric cases carrying complex chromosomal rearrangements (CCRs) to explore the clinical significance of breakpoint mapping and genotype–phenotype correlations, and we emphasize the necessity of functional validation. In the study, we explored the relationship between CCRs and NDDs, providing new insights into the genetic mechanisms. On one hand, when chromosomal karyotype abnormalities involving CCRs occur, the breakage may affect functional genes. The situation can be divided into two scenarios: if the affected gene is known and identified, then a clear and conclusive genetic diagnosis can be made. As Liu Xiaoyu et al. reported, a Chinese patient with autosomal recessive polycystic kidney disease (ARPKD) exhibited a balanced translocation and c.2507 T>C (p.V836A) in PKHD1 (Liu et al. 2024). Conversely, if the gene is not identified, this may indicate the existence of new genetic mechanisms or undiscovered genes, which require further research. Patient 1 presented with global developmental delay. Karyotype analysis revealed a pericentric inversion of chromosome 3, and WGS precisely showed that breakpoint 1 was within ROBO1, and breakpoint 2 was between DNAJC13 and ACAD11. ROBO1 encodes an axon guidance molecule receptor involved in neuronal migration and brain development, and biallelic pathogenic variants in this gene can lead to neurodevelopmental abnormalities (Huang et al. 2022). However, in this case, a pathogenic variant was detected on only one allele, with no suspicious variant identified on the other allele. This may be attributable to the following causes: (1) undetected regulatory region variants (e.g., 5′UTR, 3′UTR) or deep intronic variants; (2) epigenetic modifications (e.g., aberrant methylation); or (3) an undefined dominant inheritance mechanism. Notably, dominant phenotypic effects of ROBO1 have been reported in Drosophila models, suggesting the possibility of incomplete penetrance and phenotypic heterogeneity in humans (Huang et al. 2022). The mother of the patient had a normal phenotype, further supporting that this gene may exhibit dosage sensitivity or incomplete penetrance. DNAJC13 encodes a co‐chaperone protein of the Hsp40 family, involved in vesicle transport, endocytosis, and autophagy, and is highly expressed in central neurons (Besemer et al. 2021; Swords et al. 2024). Mutations in this gene are associated with neurodegenerative diseases such as Parkinson's disease and Lewy body disease, but its function during development remains unclear (Yoshida et al. 2018; Lorenzo‐Betancor et al. 2015). Although previous studies have explored NDD‐related genes using zebrafish models (de Abreu et al. 2020), the role of DNAJC13 as a novel candidate gene for developmental delay requires validation through cellular and animal experiments. The ACAD11 gene is highly expressed in the white matter of the human cerebellum, suggesting its potential involvement in lipid metabolism and energy regulation specific to the nervous system (He et al. 2011). Furthermore, somatic mutations of ACAD11 have been identified in retinoblastoma, implying a possible role in neuro‐oncogenesis (Bisht et al. 2022). However, there is currently no direct evidence that ACAD11 mutations lead to definite neurodegenerative diseases or neurodevelopmental disorders. Breakpoint 2 is located closer to DNAJC13 and may directly disrupt its regulatory elements, leading to loss of function or aberrant expression. In addition, ACAD11 is likely primarily indirectly affected through position effects or changes in chromatin conformation. In summary, given the lack of functional evidence, the contribution of ROBO1, DNAJC13, and ACAD11 to Patient 1's phenotype should be considered a hypothesis that requires further experimental investigation. On the other hand, when CCRs occur without any gene breakage, it is important to focus on single nucleotide variants (SNVs). Patient 2 presented with intermittent epileptic seizures. Initial karyotype analysis suggested a rearrangement of chromosome 1, but WES analyses indicated no gene disruption at the breakpoints. Therefore, the karyotype was ultimately revised to 46, XY, inv (1) (pter→p13: q21 → p13: q21 → qter). Further WES analysis identified a de novo heterozygous variant in the KCNA2 gene, NM_004974.4:c.347A>C (p.Tyr116Ser). KCNA2 encodes the voltage‐gated potassium channel subunit KV1.2, which is highly expressed in neuronal axons (Pantazis et al. 2020). Mutations in this gene frequently cause early infantile epileptic encephalopathy (Hundallah et al. 2016), associated with multiple seizure types. The ACMG criteria for the KCNA2 variant were as “Likely Pathogenic”. The clinical phenotype of this patient was highly consistent with the genotype, and the de novo mutation confirmed the diagnosis of genetic epilepsy. A summary table of KCNA2 variant phenotypes and genotypes was shown as Table 2. This table includes reported variants, their associated clinical phenotypes, and relevant references (Hundallah et al. 2016; Di Resta et al. 2015; Riazuddin et al. 2017; Symonds et al. 2019; Krenn et al. 2020; Masnada et al. 2017; Syrbe et al. 2015; Allen et al. 2016; Helbig et al. 2016; Manole et al. 2017; Hamdan et al. 2017; Pena and Coimbra 2015; Fernández‐Marmiesse et al. 2019; Parrini et al. 2017; Møller et al. 2016; Uysal et al. 2019; Abe‐Hatano et al. 2021; Sachdev et al. 2017; Zhou et al. 2018; Krygier et al. 2024; Allou et al. 2017; Dunn et al. 2020; Sonkodi et al. 2025). TABLE 2Summary table of KCNA2 variants.NoVariantAACTOVPhenotypePublication1c.128G>Ap.R43QMSBrugada syndromeDi Resta (Di Resta et al. 2015)2c.193C>Tp.R65* NSIntellectual disability, autosomal recessiveRiazuddin (Riazuddin et al. 2017)Symonds (Symonds et al. 2019)3c.209A>Tp.D70VMSNon‐acquired focal epilepsiesKrenn (Krenn et al. 2020)4c.469G>Ap.E157KMSEpileptic encephalopathyMasnada (Masnada et al. 2017)5c.637C>Tp.Q213* NSEpileptic encephalopathyMasnada (Masnada et al. 2017)6c.676G>Ap.E226KMSEpilepsy, childhood‐onsetSymonds (Symonds et al. 2019)7c.788T>Cp.I263TMSEpileptic encephalopathySyrbe (Syrbe et al. 2015)8c.869T>Gp.L290RMSEpileptic encephalopathy, early onsetAllen (Allen et al. 2016)9c.878T>Ap.L293HMSEpileptic encephalopathyMasnada (Masnada et al. 2017)10c.881G>Ap.R294HMSSpastic paraplegia & ataxiaHelbig (Helbig et al. 2016)11c.889C>Tp.R297WMSDevelopmental and epileptic encephalopathy(Manole 2017)Hamdan (Hamdan et al. 2017)12c.890G>Ap.R297QMSAtaxia & myoclonic epilepsyPena (Pena and Coimbra 2015)Syrbe (Syrbe et al. 2015)13c.894G>Tp.L298FMSEpileptic encephalopathySyrbe (Syrbe et al. 2015)14c.959C>Tp.T320IMSEpilepsy, mild language retardation, strabismus, mild ataxia, joint hyperlaxity & generalised hyperreflexiaFernández‐Marmiesse (Fernández‐Marmiesse et al. 2019)15c.971G>Cp.S324TMSEpilepsy, drug‐resistantParrini (Parrini et al. 2017)16c.982T>Gp.L328VMSEpileptic encephalopathyManole (Manole et al. 2017)17c.1070A>Gp.Q357RMSLennox‐Gastaut syndromeMøller (Møller et al. 2016)18c.1120A>Gp.T374AMSEpileptic encephalopathy, early onsetHundallah (Hundallah et al. 2016)Uysal (Uysal et al. 2019)Abe‐Hatano (Abe‐Hatano et al. 2021)19c.1192G>Tp.G398CMSEpileptic encephalopathyMasnada (Masnada et al. 2017)20c.1195G>Ap.V399MMSEpileptic encephalopathySachdev (Sachdev et al. 2017)21c.1202C>Tp.T401IMSEpileptic encephalopathyZhou (Zhou et al. 2018)22c.1214C>Tp.P405LMSEpileptic encephalopathySyrbe (Syrbe et al. 2015)Masnada (Masnada et al. 2017)Krygier (Krygier et al. 2024)23c.1223T>Cp.V408AMSRett‐like syndrome with infantile onset seizuresAllou (Allou et al. 2017)24c.1255C>Gp.R419GMSEpilepsyDunn (Dunn et al. 2020)25c.1351T>Cp.S451PMSAmyotrophic lateral sclerosisSonkodi (Sonkodi et al. 2025)Abbreviations: AAC, amino acid change; MS, missense mutation; NS, nonsense mutation; TOV, type of variant.*indicates the termination of the code. Summary table of KCNA2 variants. Abbreviations: AAC, amino acid change; MS, missense mutation; NS, nonsense mutation; TOV, type of variant. indicates the termination of the code. This study confirms that combining chromosome karyotyping with WES and/or WGS can precisely localize CCR breakpoints and provide genetic etiologies for unexplained NDDs. However, such integrated diagnostic strategies are already well established in clinical genetics (Blesson and Cohen 2020). The limitations of this study include a small sample size, a lack of functional validation for the breakpoint‐phenotype association, and the failure to exclude potential factors such as non‐coding region variants and epigenetic modifications. Future studies with larger sample sizes, multi‐omics approaches (e.g., RNA‐seq, Hi‐C), and functional assays (e.g., zebrafish models, organoids) are needed to validate these hypotheses (Carballo‐Pacoret et al. 2024; Carriba et al. 2023), particularly for cases in which breakpoints affect known genes but functional evidence is lacking. In conclusion, through precise breakpoint mapping and genotype–phenotype correlation analysis, this study provided genetic etiological clues for two pediatric cases of CCR‐associated NDDs and underscored the importance of integrating multiple techniques in clinical practice. Author Contributions Jiaci Li, Wenxuan Fan, and Nan Liu performed the literature search, analyzed data, and wrote the draft of the manuscript. Shuyue Zhang, Ping Wang, and Chunyu Gu collected the patient information, confirmed the diagnostic methods, and reviewed the manuscript. Jianbo Shu conceived and designed this manuscript. All authors read, edited, and approved the final version of the manuscript. Funding This work was supported by the Program of Tianjin Science and Technology Plan (25KPXCRC00120), the Tianjin Natural Science Foundation Project (25JCYBJC01590), the Scientific Research Plan of Tianjin Municipal Education Commission (2024ZXZD003), and the Tianjin Key Medical Discipline Construction Project (TJYXZDXK‐3‐016B). Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments We would like to express our gratitude to Mygenostics Co. Ltd. and Kingmed Diagnostics Group Co. Ltd. for their guidance and assistance in the sequencing data analysis. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.